Here are a few analogies for Edgewise Therapeutics (EWTX):

• Like a Sarepta Therapeutics (SRPT), but developing small molecule treatments for muscle disorders.
• Like a Vertex Pharmaceuticals (VRTX), but focused on small molecule therapies for muscle diseases instead of cystic fibrosis.

• EDG-5506: An orally administered small molecule therapy designed to address the root cause of dystrophinopathies, including Duchenne and Becker muscular dystrophy.

As a biopharmaceutical company focused on developing therapies for musculoskeletal diseases, Edgewise Therapeutics (EWTX) is currently in the clinical development stage. Its lead product candidate, EDG-5506, has completed Phase 1 clinical trials.

Since the company's therapeutic products are still under development and have not yet been commercialized or approved for sale, Edgewise Therapeutics does not currently have major customers that purchase its products.

• Lonza Ltd. (LONN)

Kevin Koch, Ph.D. President and Chief Executive Officer

Dr. Koch has served as President, Chief Executive Officer, and a member of Edgewise Therapeutics' board of directors since 2017. He brings over 30 years of experience in the life science industry, focusing on drug discovery, translational medicine, and clinical development. Since 2016, Dr. Koch has also been a Venture Partner with OrbiMed, a healthcare-focused investment firm. Previously, he was the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen, where he managed global drug discovery and biomarker development.

Michael Nofi Chief Financial Officer

Mr. Nofi was appointed Chief Financial Officer of Edgewise Therapeutics on November 10, 2025. Before joining Edgewise, he served as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Prior to his role at SpringWorks, Mr. Nofi was the CAO and Vice President of Global Accounting and Corporate FP&A at The Nature's Bounty Co. His career also includes senior finance positions at Acorda Therapeutics, Allergan plc, and Forest Laboratories.

Alan Russell, Ph.D. Co-Founder and Chief Scientific Officer

Dr. Russell is a co-founder of Edgewise Therapeutics and serves as its Chief Scientific Officer and a member of the board of directors.

Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer

Dr. Donovan was appointed Chief Medical Officer of Edgewise Therapeutics in April 2021. She has extensive experience in the biotechnology industry, having previously served as Chief Medical Officer and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals, where she led clinical development for Duchenne muscular dystrophy from first-in-human through Phase 3 studies. Dr. Donovan also held various positions, including Vice President of Clinical Development, at Genzyme, a company she joined through its acquisition of GelTex Pharmaceuticals. She is also a staff physician at the VA Boston Healthcare System and an Associate Clinical Professor of Medicine at Harvard Medical School.

Behrad Derakhshan, Ph.D. Chief Operating Officer

Dr. Derakhshan was promoted to Chief Operating Officer in January 2025, having previously served as Chief Business Officer since joining Edgewise in 2020. In his roles, he has been responsible for strategic planning, business development, capital formation, investor relations, corporate communications, and commercial planning. Dr. Derakhshan played a key role in the company's initial public offering and in securing several additional funding rounds.

The key risks for Edgewise Therapeutics (EWTX) are primarily associated with the inherent challenges of developing and commercializing biopharmaceutical products, particularly for a clinical-stage company with no approved products on the market.

1. Clinical Trial and Regulatory Approval Risk: As a biopharmaceutical company, Edgewise Therapeutics' success is heavily dependent on the successful development, clinical trials, and regulatory approval of its product candidates, especially sevasemten (formerly EDG-5506) for muscular dystrophies and EDG-7500 for hypertrophic cardiomyopathy. The clinical development process is lengthy, expensive, and its outcome is uncertain. There is no assurance that clinical trials will demonstrate the necessary safety and efficacy to satisfy regulatory authorities like the FDA or EMA, or that they will produce positive results. For example, while promising long-term results have been reported for sevasemten in Becker muscular dystrophy, top-line results from the pivotal GRAND CANYON study are still pending in Q4 2026. Failures at any stage of clinical development, including unexpected adverse events such as the atrial fibrillation risk noted for EDG-7500, could delay or prevent regulatory approval and commercialization, substantially harming the business.
2. Financial Risk and Lack of Approved Products: Edgewise Therapeutics is an early-stage company without any approved products for commercial sale, meaning it currently generates no revenue. The company has a limited operating history and incurs significant net losses, primarily due to high research and development expenses, such as the full-year 2025 net loss of $167.8 million. This financial profile complicates the evaluation of its business viability. The company is continuously burning cash and relies on securing additional capital through equity or debt offerings to fund its ongoing operations, clinical advancements, and future commercialization activities. Fluctuations in the availability of capital due to macroeconomic events could impact its ability to raise necessary funds.
3. Dependence on Third Parties for Clinical Trials and Manufacturing: Edgewise Therapeutics relies on third parties for conducting its clinical trials and for manufacturing its product candidates. There is an operational risk that these third parties may not perform satisfactorily, which could lead to delays in development or commercialization efforts. Any issues with the production of drugs by third-party manufacturers or changes in manufacturing methods or formulations could also pose significant challenges.

Edgewise Therapeutics' lead product candidate, EDG-5506, targets Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).

Duchenne Muscular Dystrophy (DMD)

• The global Duchenne muscular dystrophy drugs market size was estimated at USD 3.47 billion in 2023 and is projected to reach USD 9.91 billion by 2030.
• Another estimate places the global DMD drugs market at USD 2.3 billion in 2023, with an expected increase to USD 5.5 billion by 2032.
• The Duchenne muscular dystrophy market size in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) was around USD 2,150 million in 2023.
• The United States accounts for the largest Duchenne muscular dystrophy market size, at approximately USD 1,900 million in 2023. North America dominated the global Duchenne muscular dystrophy drugs market with a 45.0% revenue share in 2023.

Becker Muscular Dystrophy (BMD)

• The global Becker muscular dystrophy treatment market size was valued at USD 1.92 billion in 2024 and is expected to reach USD 2.83 billion by 2032.
• The Becker muscular dystrophy market across the top 7 markets (US, EU4, UK, and Japan) reached a value of USD 880.6 million in 2024 and is expected to reach USD 1,355.1 million by 2035.
• In 2024, the United States accounted for the largest Becker Muscular Dystrophy market size compared to EU4, the UK, and Japan. North America dominated the Becker muscular dystrophy treatment market with the largest revenue share of 42.8% in 2024.

Edgewise Therapeutics (EWTX) is a biopharmaceutical company focused on developing therapies for musculoskeletal diseases and serious cardiac conditions. The company's future revenue growth over the next 2-3 years is anticipated to be driven by the following key factors:

1. Commercialization of Sevasemten (EDG-5506) for Becker Muscular Dystrophy: Edgewise Therapeutics expects to announce top-line data from the pivotal GRAND CANYON study for sevasemten in Becker muscular dystrophy in the fourth quarter of 2026. A New Drug Application (NDA) submission for sevasemten in Becker is planned for the first half of 2027, with a potential commercial launch anticipated by the fourth quarter of 2027 and the first full year of revenue in 2028. Sevasemten has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Becker muscular dystrophy, and analysts project significant revenue in 2027 and 2028 if commercialized successfully. The market potential for this program is estimated at $5 billion.
2. Advancement of Sevasemten (EDG-5506) for Duchenne Muscular Dystrophy: The company has reported positive results from its Phase 2 Duchenne trials (LYNX and FOX) for sevasemten. Edgewise plans to initiate a pivotal Phase 3 study for Duchenne muscular dystrophy in 2026. EDG-5506 has already been granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations by the FDA for Duchenne muscular dystrophy, which could expedite its development and review process.
3. Progression of EDG-7500 for Hypertrophic Cardiomyopathy (HCM): Edgewise Therapeutics anticipates reporting 12-week Part D data from the Phase 2 CIRRUS-HCM study for EDG-7500 in the first half of 2026. These results are expected to inform the design and initiation of Phase 3 trials in both obstructive and nonobstructive HCM in the fourth quarter of 2026. EDG-7500 is considered a differentiated treatment with a potential market size of $10 billion.
4. Development of EDG-15400 for Heart Failure with Preserved Ejection Fraction (HFpEF): The company expects to announce top-line results from its Phase 1 healthy adult trial of EDG-15400 in the first half of 2026. Following this, Edgewise plans to initiate a Phase 2 trial for EDG-15400 in participants with heart failure with preserved ejection fraction (HFpEF) in the second half of 2026.

Capital Allocation Decisions for Edgewise Therapeutics (EWTX)

Share Issuance

• Edgewise Therapeutics secured $240 million in funding in November 2024, representing a significant share issuance.
• The number of outstanding shares increased by 11.38% in the year leading up to early 2026.
• The company became public through an Initial Public Offering (IPO) in 2021.

Inbound Investments

• Edgewise Therapeutics received $240 million in funding in November 2024, intended to advance its pipeline of novel treatments and clinical trials for muscle diseases.

Capital Expenditures

• Capital expenditures totaled approximately $256,000 over the 12 months ending in early 2026.
• The company reported capital expenditures of $73,000 in the fourth quarter of 2025.
• Capital is primarily focused on supporting ongoing clinical trials and near-term development plans for its muscular dystrophy and cardiovascular programs.